PLSE
Pulse Biosciences Inc
$21.83
-$0.82(-3.62%)
46
Overall
40
Value
54
Tech
44
Quality
Market Cap
$1.18B
Volume
270.84K
52W Range
$12.56 - $26.30
Target Price
$30.00
Company Overview
| Mkt Cap | $1.18B | Price | $21.83 |
| Volume | 270.84K | Change | -3.62% |
| P/E Ratio | -16.3 | Open | $22.70 |
| Revenue | $350.0K | Prev Close | $22.65 |
| Net Income | $-72.8M | 52W Range | $12.56 - $26.30 |
| Div Yield | N/A | Target | $30.00 |
| Overall | 46 | Value | 40 |
| Quality | 44 | Technical | 54 |
No chart data available
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Latest News
Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data
TipRanks Auto-Generated Newsdesk•2 days ago
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche
TipRanks Clinical-Trials-Auto-Generated Newsdesk•12 days ago
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche
TipRanks Clinical-Trials-Auto-Generated Newsdesk•12 days ago
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy
TipRanks Auto-Generated Newsdesk•13 days ago
Mizuho Securities Keeps Their Buy Rating on Pulse Biosciences (PLSE)
TipRanks Auto-Generated Intelligence Newsdesk•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PLSE | $21.83 | -3.6% | 270.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |